Phase II, Dose Ranging, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2011
At a glance
- Drugs Aplindore (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Aug 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
- 07 Jun 2009 Efficacy results presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.
- 15 Oct 2008 Positive top-line results announced by Neurogen Corporation.